Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015)

Ocugen (OCGN) posted Long-Term Deferred Tax of $1.1 million for Q3 2015, up 0.86% on a QoQ basis from $1.0 million in Q2 2015.

Ocugen (OCGN) Long-Term Deferred Tax (2014 - 2015) Analysis & Trends

Ocugen's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $1.1 million for Q3 2015.

Quarterly Long-Term Deferred Tax changed N/A year-over-year to $1.1 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $1.1 million (changed N/A YoY) and the FY2014 annual result came in at $651000.0, changed N/A from the prior year.
Long-Term Deferred Tax was $1.1 million for Q3 2015 at Ocugen, up from $1.0 million in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $1.1 million in Q3 2015 and bottomed at $651000.0 in Q4 2014.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Ocugen	63.79 Mn	63.79 Mn	-

Download Data